Enteral Feeding IntoleranceNCT07876141
Continuous Versus Intermittent Enteral Feeding and Gastric Residual Volume in Critically Ill Patients
A study testing Continuous Enteral Feeding and Intermittent Enteral Feeding in people with Enteral Feeding Intolerance and Critical Illness, run by Viet Duc University Hospital at 1 site in Vietnam.
Trial summary
This study will compare two commonly used methods of enteral feeding in critically ill adults: continuous feeding and intermittent feeding. The main purpose is to determine whether the amount of feeding fluid remaining in the stomach differs between the two methods. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Enteral Feeding Intolerance, Critical Illness
- What is being tested?
- Continuous Enteral Feeding and Intermittent Enteral Feeding
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 76 participants
- Where
- 1 siteVietnam
- Study dates
- 15 Oct 2026to 1 Oct 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 to 80 years.
- Currently treated in an intensive care unit and has a clinical indication for gastric enteral nutrition through a nasogastric or orogastric tube.
- The gastrointestinal tract is considered usable for enteral nutrition according to the treating physician.
- Expected to remain in the intensive care unit and to be available for study follow-up for 72 hours after randomization, unless a prespecified early stopping criterion occurs.
- A gastric enteral nutrition plan is in place; the enteral formula and energy/protein targets are determined by the treating physician in consultation with the Department of Nutrition before randomization.
- Written informed consent is provided by the participant or a legally authorized representative.
Who cannot join
- Previous gastrectomy, pyloric stenosis, or recent gastric or duodenal surgery that alters gastric anatomy or function and may affect ultrasound-based gastric volume estimation.
- Contraindication to enteral nutrition, including bowel obstruction, severe ileus, gastrointestinal perforation, intestinal ischemia or necrosis, severe gastrointestinal bleeding, or another condition requiring complete cessation of enteral feeding.
- Expected death, transfer out of the intensive care unit, or removal of the gastric tube in the near term such that 72-hour study follow-up is not feasible.
- Receiving exclusive parenteral nutrition with no plan to initiate gastric enteral feeding.
- Pregnancy.
- Uncontrolled shock or hemodynamic instability at screening, defined as norepinephrine ≥0.3 micrograms/kg/min or an equivalent vasopressor requirement according to the treating physician.
Show all 10Show fewer
- Unable to tolerate brief right lateral positioning for gastric ultrasonography because of hemodynamic or respiratory instability, spinal injury or fixation, contraindication to turning, or another safety concern.
- Gastric antrum cannot be adequately visualized at screening because of an inadequate acoustic window, surgical wound or dressing, subcutaneous emphysema, excessive gas, or another reason.
- Participant or legally authorized representative declines participation.
- Participant lacks capacity to provide consent and no legally authorized representative is available at enrollment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Vietnam1 site, 1 recruiting
- Recruiting
Viet Duc University Hospital
Hà Nội, 100000
Thu Phuong Hoang, MD, +84 943 671 709, hoangthuphuongdb@gmail.com
Thu Phuong Hoang, MD
About this study
Official title: Comparison of Gastric Residual Volume Between Continuous and Intermittent Enteral Feeding in Critically Ill Patients
This study will compare two commonly used methods of enteral feeding in critically ill adults: continuous feeding and intermittent feeding. The main purpose is to determine whether the amount of feeding fluid remaining in the stomach differs between the two methods.
A total of 76 participants will be randomly assigned to receive either continuous gastric feeding or intermittent gastric feeding every 4 hours. Gastric ultrasound will be performed at the bedside before starting the assigned feeding method and then every 4 hours for 72 hours. The study will also record symptoms of feeding intolerance, such as vomiting, regurgitation, abdominal distension, diarrhea, constipation, feeding interruptions, and the amount of prescribed nutrition actually delivered.
Read the detailed description
This is a single-center, prospective, open-label, parallel-group randomized controlled trial conducted in critically ill adults who require gastric enteral nutrition.
A total of 76 participants will be randomly allocated in a 1:1 ratio to continuous enteral feeding or intermittent enteral feeding. Before randomization, the treating physician, in consultation with the Department of Nutrition, will determine the enteral formula and the daily energy and protein targets for each participant. The study intervention is the method used to deliver the prescribed nutrition.
In the continuous-feeding group, the prescribed daily enteral volume will be delivered through a gastric tube using an enteral feeding pump at a stable hourly rate. In the intermittent-feeding group, the prescribed daily volume will be divided into six feeds administered every 4 hours, with each feed delivered over approximately 30 to 60 minutes.
Gastric ultrasonography will be performed at baseline before starting the assigned feeding method and every 4 hours for 72 hours. The primary outcome is the mean ultrasound-estimated gastric residual volume calculated from the 18 post-baseline measurements obtained from 4 to 72 hours. The study will also evaluate enteral feeding intolerance, vomiting or regurgitation, progressive abdominal distension, diarrhea, constipation, episodes of elevated gastric residual volume, suspected aspiration, feeding interruptions, use of prokinetic medication, and the proportion of the prescribed energy target actually delivered at 24, 48, and 72 hours.
All clinical decisions related to patient safety, including reducing, delaying, or stopping enteral feeding, will remain under the responsibility of the treating physician.
- Conditions
- Enteral Feeding Intolerance, Critical Illness
- Being tested
- Continuous Enteral Feeding, Intermittent Enteral Feeding
- Keywords
- continuous enteral feeding, intermittent enteral feeding, gastric ultrasound, gastric residual volume, feeding intolerance, antral cross-sectional area, intensive care unit, enteral nutrition
- Medical subject headings
- Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous Enteral FeedingOther
The prescribed daily enteral nutrition will be delivered continuously through a gastric tube using an enteral feeding pump at a stable hourly rate. The hourly rate will be calculated as the total prescribed volume for 24 hours divided by 24.
Intermittent Enteral FeedingOther
The prescribed daily enteral nutrition will be divided into six equal feeds administered through a gastric tube every 4 hours. Each feed will be administered over approximately 30 to 60 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Continuous Enteral Feeding | Experimental | Participants assigned to this arm will receive the prescribed daily enteral nutrition continuously through a gastric tube using an enteral feeding pump. The prescribed daily volume will be delivered at a stable hourly rate calculated as the total prescribed volume for 24 hours divided by 24. Receives: Other: Continuous Enteral Feeding |
| Intermittent Enteral Feeding | Active comparator | Participants assigned to this arm will receive the prescribed daily enteral nutrition through a gastric tube in six intermittent feeds administered every 4 hours. The prescribed daily volume will be divided equally among the six feeds, and each feed will be administered over approximately 30 to 60 minutes. Receives: Other: Intermittent Enteral Feeding |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Ultrasound-Estimated Gastric Residual Volume Over 72 Hours
Mean ultrasound-estimated gastric residual volume (GRV), in milliliters (mL). For each participant, the primary endpoint will be calculated as the arithmetic mean of 18 post-baseline GRV measurements obtained every 4 hours from 4 hours through 72 hours after initiation of the assigned feeding strategy. The baseline measurement obtained before initiation of the assigned feeding strategy will not be included in this mean. Gastric antral cross-sectional area (CSA) will be calculated as AP × CC × π/4, where AP is the anteroposterior diameter and CC is the craniocaudal diameter. GRV will be estimated using the Perlas formula: GRV (mL) = 27.0 + 14.6 × CSA (cm²) - 1.28 × age (years). Calculated values below 0 mL will be set to 0 mL.
Measured: From 4 hours after initiation of the assigned feeding strategy through 72 hours
Secondary outcomes (14)
Participants With at Least One GRV >250 mL
Number and percentage of participants with at least one ultrasound-estimated gastric residual volume (GRV) measurement greater than 250 mL during post-baseline follow-up.
Measured: From 4 hours after initiation of the assigned feeding strategy through 72 hours
Participants With at Least One GRV >500 mL
Number and percentage of participants with at least one ultrasound-estimated gastric residual volume (GRV) measurement greater than 500 mL during post-baseline follow-up.
Measured: From 4 hours after initiation of the assigned feeding strategy through 72 hours
Enteral Feeding Intolerance
Number and percentage of participants with at least one gastrointestinal manifestation that causes the treating physician to reduce, delay, or temporarily interrupt enteral feeding and/or to initiate supportive treatment.
Measured: From randomization through 72 hours
Vomiting or Regurgitation
Number and percentage of participants with at least one episode of vomiting or regurgitation documented by clinical staff during enteral feeding.
Measured: From randomization through 72 hours
Progressive Abdominal Distension
Number and percentage of participants with new-onset abdominal distension or an increase in abdominal distension compared with the previous clinical assessment, as documented by a physician or nurse.
Measured: From randomization through 72 hours
Diarrhea
Number and percentage of participants with diarrhea, defined as at least 3 episodes of loose stool within 24 hours or a diagnosis of diarrhea by the treating physician.
Measured: From randomization through 72 hours
Constipation
Number and percentage of participants with constipation, defined as no bowel movement for at least 3 days or the need for therapeutic intervention for constipation during follow-up.
Measured: From randomization through 72 hours
Suspected Pulmonary Aspiration
Number and percentage of participants with at least one clinically suspected pulmonary aspiration event documented by the treating team during enteral feeding.
Measured: From randomization through 72 hours
Number of Enteral Feeding Reduction or Interruption Episodes
Number of episodes in which enteral feeding is reduced or temporarily interrupted during the 72-hour follow-up. The reason for each episode will be recorded.
Measured: From randomization through 72 hours
Total Duration of Enteral Feeding Interruption
Total cumulative duration, in minutes, during which enteral feeding is temporarily interrupted during the 72-hour follow-up.
Measured: From randomization through 72 hours
New Use of a Prokinetic Agent
Number and percentage of participants newly started on a prokinetic agent, such as metoclopramide or erythromycin, after randomization because of feeding intolerance or impaired gastric emptying.
Measured: From randomization through 72 hours
Percentage of Prescribed Energy Target Achieved at 24 Hours
Percentage of the prescribed energy target actually delivered during the first 24 hours, calculated as cumulative actual enteral energy delivered divided by the cumulative prescribed enteral energy target for the same period, multiplied by 100.
Measured: At 24 hours
Percentage of Prescribed Energy Target Achieved at 48 Hours
Percentage of the prescribed energy target actually delivered through 48 hours, calculated as cumulative actual enteral energy delivered divided by the cumulative prescribed enteral energy target for the same period, multiplied by 100.
Measured: At 48 hours
Percentage of Prescribed Energy Target Achieved at 72 Hours
Percentage of the prescribed energy target actually delivered through 72 hours, calculated as cumulative actual enteral energy delivered divided by the cumulative prescribed enteral energy target for the same period, multiplied by 100.
Measured: At 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2026
- Study start15 Oct 2026
- Primary completion1 Oct 2027 (estimated)
- Study completion1 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Enteral Feeding IntoleranceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 76 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Viet Duc University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07876141
- Sponsor's protocol ID
- PhuongK2
- Other IDs
- HMUIRB2962
- Status last verified
- Oct 2026
- First submitted
- 6 Oct 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared outside the approved research team. Study results will be reported in aggregate form without direct identifiers.
Publications
Ankalagi B, Singh PM, Rewari V, Ramachandran R, Aggarwal R, Soni KD, Das D, Madhusudhan KS, Srivastava DN, Kaur M, Trikha A. Serial Ultrasonographic-measurement of Gastric Residual Volume in Critically Ill Patients for Prediction of Gastric Tube Feed Intolerance. Indian J Crit Care Med. 2022 Sep;26(9):987-992. doi: 10.5005/jp-journals-10071-24296.
PubMed 36213700Sharma V, Gudivada D, Gueret R, Bailitz J. Ultrasound-Assessed Gastric Antral Area Correlates With Aspirated Tube Feed Volume in Enterally Fed Critically Ill Patients. Nutr Clin Pract. 2017 Apr;32(2):206-211. doi: 10.1177/0884533616681530. Epub 2016 Dec 16.
PubMed 28362573Hamada SR, Garcon P, Ronot M, Kerever S, Paugam-Burtz C, Mantz J. Ultrasound assessment of gastric volume in critically ill patients. Intensive Care Med. 2014 Jul;40(7):965-72. doi: 10.1007/s00134-014-3320-x. Epub 2014 May 20.
PubMed 24841699Perlas A, Mitsakakis N, Liu L, Cino M, Haldipur N, Davis L, Cubillos J, Chan V. Validation of a mathematical model for ultrasound assessment of gastric volume by gastroscopic examination. Anesth Analg. 2013 Feb;116(2):357-63. doi: 10.1213/ANE.0b013e318274fc19. Epub 2013 Jan 9.
PubMed 23302981Lee HY, Lee JK, Kim HJ, Ju DL, Lee SM, Lee J. Continuous versus Intermittent Enteral Tube Feeding for Critically Ill Patients: A Prospective, Randomized Controlled Trial. Nutrients. 2022 Feb 4;14(3):664. doi: 10.3390/nu14030664.
PubMed 35277023Heffernan AJ, Talekar C, Henain M, Purcell L, Palmer M, White H. Comparison of continuous versus intermittent enteral feeding in critically ill patients: a systematic review and meta-analysis. Crit Care. 2022 Oct 25;26(1):325. doi: 10.1186/s13054-022-04140-8.
PubMed 36284334
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Gastric Residual Volume Between Continuous and Intermittent Enteral Feeding in Critically Ill Patients
- ClinicalTrials.gov ID
- NCT07876141
- Acronym / sponsor ID
- PhuongK2
- Conditions
- Enteral Feeding Intolerance, Critical Illness
- Keywords
- continuous enteral feeding, intermittent enteral feeding, gastric ultrasound, gastric residual volume, feeding intolerance, antral cross-sectional area, intensive care unit, enteral nutrition
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 76 participants (estimated)
- Lead sponsor
- Viet Duc University HospitalUniversity, hospital or other
- Study start
- 15 Oct 2026 (actual)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 1 Oct 2027 (estimated)
- First posted
- 15 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will compare two commonly used methods of enteral feeding in critically ill adults: continuous feeding and intermittent feeding. The main purpose is to determine whether the amount of feeding fluid remaining in the stomach differs between the two methods.
A total of 76 participants will be randomly assigned to receive either continuous gastric feeding or intermittent gastric feeding every 4 hours. Gastric ultrasound will be performed at the bedside before starting the assigned feeding method and then every 4 hours for 72 hours. The study will also record symptoms of feeding intolerance, such as vomiting, regurgitation, abdominal distension, diarrhea, constipation, feeding interruptions, and the amount of prescribed nutrition actually delivered.
Detailed description
This is a single-center, prospective, open-label, parallel-group randomized controlled trial conducted in critically ill adults who require gastric enteral nutrition.
A total of 76 participants will be randomly allocated in a 1:1 ratio to continuous enteral feeding or intermittent enteral feeding. Before randomization, the treating physician, in consultation with the Department of Nutrition, will determine the enteral formula and the daily energy and protein targets for each participant. The study intervention is the method used to deliver the prescribed nutrition.
In the continuous-feeding group, the prescribed daily enteral volume will be delivered through a gastric tube using an enteral feeding pump at a stable hourly rate. In the intermittent-feeding group, the prescribed daily volume will be divided into six feeds administered every 4 hours, with each feed delivered over approximately 30 to 60 minutes.
Gastric ultrasonography will be performed at baseline before starting the assigned feeding method and every 4 hours for 72 hours. The primary outcome is the mean ultrasound-estimated gastric residual volume calculated from the 18 post-baseline measurements obtained from 4 to 72 hours. The study will also evaluate enteral feeding intolerance, vomiting or regurgitation, progressive abdominal distension, diarrhea, constipation, episodes of elevated gastric residual volume, suspected aspiration, feeding interruptions, use of prokinetic medication, and the proportion of the prescribed energy target actually delivered at 24, 48, and 72 hours.
All clinical decisions related to patient safety, including reducing, delaying, or stopping enteral feeding, will remain under the responsibility of the treating physician.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Continuous Enteral Feeding | Experimental | Other: Continuous Enteral FeedingParticipants assigned to this arm will receive the prescribed daily enteral nutrition continuously through a gastric tube using an enteral feeding pump. The prescribed daily volume will be delivered at a stable hourly rate calculated as the total prescribed volume for 24 hours divided by 24. |
| Intermittent Enteral Feeding | Active comparator | Other: Intermittent Enteral FeedingParticipants assigned to this arm will receive the prescribed daily enteral nutrition through a gastric tube in six intermittent feeds administered every 4 hours. The prescribed daily volume will be divided equally among the six feeds, and each feed will be administered over approximately 30 to 60 minutes. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 18 to 80 years.
- Currently treated in an intensive care unit and has a clinical indication for gastric enteral nutrition through a nasogastric or orogastric tube.
- The gastrointestinal tract is considered usable for enteral nutrition according to the treating physician.
- Expected to remain in the intensive care unit and to be available for study follow-up for 72 hours after randomization, unless a prespecified early stopping criterion occurs.
- A gastric enteral nutrition plan is in place; the enteral formula and energy/protein targets are determined by the treating physician in consultation with the Department of Nutrition before randomization.
Key exclusion criteria (10 listed)
- Previous gastrectomy, pyloric stenosis, or recent gastric or duodenal surgery that alters gastric anatomy or function and may affect ultrasound-based gastric volume estimation.
- Contraindication to enteral nutrition, including bowel obstruction, severe ileus, gastrointestinal perforation, intestinal ischemia or necrosis, severe gastrointestinal bleeding, or another condition requiring complete cessation of enteral feeding.
- Expected death, transfer out of the intensive care unit, or removal of the gastric tube in the near term such that 72-hour study follow-up is not feasible.
- Receiving exclusive parenteral nutrition with no plan to initiate gastric enteral feeding.
- Pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous Enteral FeedingThe prescribed daily enteral nutrition will be delivered continuously through a gastric tube using an enteral feeding pump at a stable hourly rate. The hourly rate will be calculated as the total prescribed volume for 24 hours divided by 24. | Other | Continuous Enteral Feeding |
| Intermittent Enteral FeedingThe prescribed daily enteral nutrition will be divided into six equal feeds administered through a gastric tube every 4 hours. Each feed will be administered over approximately 30 to 60 minutes. | Other | Intermittent Enteral Feeding |
Primary outcome
Mean Ultrasound-Estimated Gastric Residual Volume Over 72 Hours
Time frame: From 4 hours after initiation of the assigned feeding strategy through 72 hours
Mean ultrasound-estimated gastric residual volume (GRV), in milliliters (mL). For each participant, the primary endpoint will be calculated as the arithmetic mean of 18 post-baseline GRV measurements obtained every 4 hours from 4 hours through 72 hours after initiation of the assigned feeding strategy. The baseline measurement obtained before initiation of the assigned feeding strategy will not be included in this mean. Gastric antral cross-sectional area (CSA) will be calculated as AP × CC × π/4, where AP is the anteroposterior diameter and CC is the craniocaudal diameter. GRV will be estimated using the Perlas formula: GRV (mL) = 27.0 + 14.6 × CSA (cm²) - 1.28 × age (years). Calculated values below 0 mL will be set to 0 mL.
14 secondary outcomes
Participants With at Least One GRV >250 mL
Time frame: From 4 hours after initiation of the assigned feeding strategy through 72 hours
Participants With at Least One GRV >500 mL
Time frame: From 4 hours after initiation of the assigned feeding strategy through 72 hours
Enteral Feeding Intolerance
Time frame: From randomization through 72 hours
Vomiting or Regurgitation
Time frame: From randomization through 72 hours
Progressive Abdominal Distension
Time frame: From randomization through 72 hours
Diarrhea
Time frame: From randomization through 72 hours
Constipation
Time frame: From randomization through 72 hours
Suspected Pulmonary Aspiration
Time frame: From randomization through 72 hours
Number of Enteral Feeding Reduction or Interruption Episodes
Time frame: From randomization through 72 hours
Total Duration of Enteral Feeding Interruption
Time frame: From randomization through 72 hours
New Use of a Prokinetic Agent
Time frame: From randomization through 72 hours
Percentage of Prescribed Energy Target Achieved at 24 Hours
Time frame: At 24 hours
Percentage of Prescribed Energy Target Achieved at 48 Hours
Time frame: At 48 hours
Percentage of Prescribed Energy Target Achieved at 72 Hours
Time frame: At 72 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Background: PubMed 36213700Ankalagi B, Singh PM, Rewari V, Ramachandran R, Aggarwal R, Soni KD, Das D, Madhusudhan KS, Srivastava DN, Kaur M, Trikha A. Serial Ultrasonographic-measurement of Gastric Residual Volume in Critically Ill Patients for Prediction of Gastric Tube Feed Intolerance. Indian J Crit Care Med. 2022 Sep;26(9):987-992. doi: 10.5005/jp-journals-10071-24296.
- Background: PubMed 28362573Sharma V, Gudivada D, Gueret R, Bailitz J. Ultrasound-Assessed Gastric Antral Area Correlates With Aspirated Tube Feed Volume in Enterally Fed Critically Ill Patients. Nutr Clin Pract. 2017 Apr;32(2):206-211. doi: 10.1177/0884533616681530. Epub 2016 Dec 16.
- Background: PubMed 24841699Hamada SR, Garcon P, Ronot M, Kerever S, Paugam-Burtz C, Mantz J. Ultrasound assessment of gastric volume in critically ill patients. Intensive Care Med. 2014 Jul;40(7):965-72. doi: 10.1007/s00134-014-3320-x. Epub 2014 May 20.
- Background: PubMed 23302981Perlas A, Mitsakakis N, Liu L, Cino M, Haldipur N, Davis L, Cubillos J, Chan V. Validation of a mathematical model for ultrasound assessment of gastric volume by gastroscopic examination. Anesth Analg. 2013 Feb;116(2):357-63. doi: 10.1213/ANE.0b013e318274fc19. Epub 2013 Jan 9.
- Background: PubMed 35277023Lee HY, Lee JK, Kim HJ, Ju DL, Lee SM, Lee J. Continuous versus Intermittent Enteral Tube Feeding for Critically Ill Patients: A Prospective, Randomized Controlled Trial. Nutrients. 2022 Feb 4;14(3):664. doi: 10.3390/nu14030664.
- Background: PubMed 36284334Heffernan AJ, Talekar C, Henain M, Purcell L, Palmer M, White H. Comparison of continuous versus intermittent enteral feeding in critically ill patients: a systematic review and meta-analysis. Crit Care. 2022 Oct 25;26(1):325. doi: 10.1186/s13054-022-04140-8.
- Individual participant dataSharing planned: No. Individual participant data will not be shared outside the approved research team. Study results will be reported in aggregate form without direct identifiers.
Related trials for Enteral Feeding Intolerance
Not yet recruitingObservational study
FACTORS AFFECTİNG ENTERAL FEEDİNG INTOLERANCE İN INTENSİVE CARE UNİT PATİENTS
Patients Who Receive Enteral Nutrition for at Least 72 Hours in the Intensive Care Unit Will be Included in the Study
Recruiting
Effect of Blenderized Enteral Tube Feeds on Pediatric Upper Gastrointestinal Tract Physiology
Enteral Feeding Intolerance
Not yet recruitingObservational study
Gut Microbiota Structure, Functional and Metabolic Profiles, and Composite Biomarkers in ICU Adults With Refractory Enteral Feeding Intolerance
Refractory Enteral Feeding Intolerance, Gut Microbiota
Not yet recruiting
Transcutaneous Auricular Stimulation Targeting Enteral Feeding Intolerance
Enteral Feeding Intolerance, ICU
Not yet recruitingObservational study
JLU_Nutr_FI Registry: A Prospective Registry of Feeding Intolerance in Critically Ill Patients
Critical Illness, Feeding Intolerance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous Enteral Feeding and Intermittent Enteral Feeding in people with Enteral Feeding Intolerance and Critical Illness, run by Viet Duc University Hospital at 1 site in Vietnam.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Thu Phuong Hoang, MD (+84 943 671 709, hoangthuphuongdb@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Ultrasound-Estimated Gastric Residual Volume Over 72 Hours (time frame: From 4 hours after initiation of the assigned feeding strategy through 72 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07876141, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.